PMID- 35432194
OWN - NLM
STAT- MEDLINE
DCOM- 20220419
LR  - 20220519
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in 
      Patients With Type 2 Diabetes.
PG  - 677202
LID - 10.3389/fendo.2022.677202 [doi]
LID - 677202
AB  - OBJECTIVE: Exenatide has been demonstrated beneficial effects on patients with 
      type 2 diabetes mellitus (T2DM) regarding lipid metabolism. However, the 
      potential mechanism remains unclear. We used a lipidomic approach to evaluate 
      lipid changes in response to treatment with exenatide in T2DM patients. METHODS: 
      Serum lipidomic profiles of 35 newly diagnosed T2DM patients (before and after 
      exenatide treatment) and 20 age-matched healthy controls were analyzed by 
      ultrahigh-performance liquid chromatography-tandem quadrupole time-of-flight mass 
      spectrometry. RESULTS: A total of 45 lipid species including sphingomyelins 
      (SMs), ceramides (CERs), lysophosphatidylcholines (LPCs), 
      phosphatidylethanolamines (PEs), lysophosphatidylethanolamines (LPEs) and 
      phosphatidylcholines (PCs) were identified in all participants. Compared to the 
      healthy controls, 13 lipid species [SM (d18:1/18:0, d18:1/18:1), Cer (d18:1/18:0, 
      d18:1/16:0, d18:1/20:0, d18:1/24:1), LPC (15:0, 16:0, 17:0), PC (19:0/19:0), LPE 
      (18:0) and PE (16:0/22:6, 18:0/22:6)] were markedly increased in the T2DM group, 
      while PE (17:0/17:0) and PC (18:1/18:0) were decreased (P < 0.05). The serum SM 
      (d18:1/18:0, d18:1/18:1), LPC (16:0), and LPE (18:0) were significantly decreased 
      after exenatide treatment, which was accompanied by the amelioration of lipids 
      and glycemic parameters (TC, LDL-C, ApoA-I, FCP and HbA(1c)) in T2DM patients. 
      The chord diagrams showed distinct correlation patterns between lipid classes and 
      subclasses among healthy controls, T2DM patients before and after exenatide 
      treatment. CONCLUSION: Our results revealed that the therapeutic benefits of 
      exenatide on T2DM might be involved in the improved lipid metabolism, especially 
      SM, LPC, and LPE. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, identifier 
      NCT03297879.
CI  - Copyright (c) 2022 Zhang, Hu, An, Wang, Liu and Wang.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Hu, Yanjin
AU  - Hu Y
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
FAU - An, Yu
AU  - An Y
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Qiu
AU  - Wang Q
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Guang
AU  - Wang G
AD  - Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03297879
PT  - Journal Article
DEP - 20220331
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Ceramides)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Ceramides
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Exenatide
MH  - Humans
MH  - Lipid Metabolism
MH  - *Lipidomics
PMC - PMC9009038
OTO - NOTNLM
OT  - exenatide
OT  - lipidomics
OT  - serum
OT  - treatment
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/19 06:00
MHDA- 2022/04/20 06:00
PMCR- 2022/01/01
CRDT- 2022/04/18 06:33
PHST- 2021/03/07 00:00 [received]
PHST- 2022/03/07 00:00 [accepted]
PHST- 2022/04/18 06:33 [entrez]
PHST- 2022/04/19 06:00 [pubmed]
PHST- 2022/04/20 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.677202 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Mar 31;13:677202. doi: 
      10.3389/fendo.2022.677202. eCollection 2022.